Michael Schleuning
Overview
Explore the profile of Michael Schleuning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
833
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weissinger E, Metzger J, Schleuning M, Schmid C, Messinger D, Beutel G, et al.
Leukemia
. 2020 Oct;
35(6):1763-1772.
PMID: 33082512
Acute graft-versus-host disease (aGvHD) contributes to about 50% of transplant-related mortality (non-relapse mortality) after allogeneic hematopoietic stem cell transplantation (HSCT). Here the predictive value of a urinary proteomic profile (aGvHD_MS17)...
2.
Burchert A, Bug G, Fritz L, Finke J, Stelljes M, Rollig C, et al.
J Clin Oncol
. 2020 Jul;
38(26):2993-3002.
PMID: 32673171
Purpose: Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the like tyrosine kinase 3 gene (ITD) have a...
3.
Schmid C, Labopin M, Schaap N, Veelken H, Schleuning M, Stadler M, et al.
Br J Haematol
. 2018 Nov;
184(5):782-787.
PMID: 30467839
Strategies for relapse prevention after allogeneic transplantation in acute leukaemia are warranted. A registry-based matched-pair analysis evaluated the efficacy of prophylactic donor lymphocyte infusion (proDLI). Adults receiving proDLI in complete...
4.
Schmid C, de Wreede L, van Biezen A, Finke J, Ehninger G, Ganser A, et al.
Haematologica
. 2017 Nov;
103(2):237-245.
PMID: 29101205
No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated...
5.
Heidenreich S, Ziagkos D, de Wreede L, van Biezen A, Finke J, Platzbecker U, et al.
Biol Blood Marrow Transplant
. 2016 Oct;
23(1):44-52.
PMID: 27720995
In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome...
6.
Wolff D, Ayuk F, Elmaagacli A, Bertz H, Lawitschka A, Schleuning M, et al.
Biol Blood Marrow Transplant
. 2013 Feb;
19(5):767-76.
PMID: 23376495
To assess current clinical practice in diagnosis and treatment of acute graft-versus-host disease (aGVHD), we performed a survey among German, Austrian, and Swiss allogeneic hematopoietic stem cell transplantation (allo-HSCT) centers....
7.
Pfeiffer T, Schleuning M, Mayer J, Haude K, Tischer J, Buchholz S, et al.
Haematologica
. 2012 Sep;
98(4):518-25.
PMID: 22983588
Based on molecular aberrations, in particular the NPM1 mutation (NPM1(mut)) and the FLT3 internal tandem duplication (Flt3-ITD), prognostic subgroups have been defined among patients with acute myeloid leukemia with normal...
8.
Wolf D, von Lilienfeld-Toal M, Wolf A, Schleuning M, von Bergwelt-Baildon M, Held S, et al.
Blood
. 2011 Sep;
119(1):16-25.
PMID: 21948301
Acute and chronic graft-versus-host disease (GVHD) are potentially lethal complications after stem cell transplantation (SCT). Steroids are the appropriate first-line treatment for both. However, if patients do not adequately benefit...
9.
Jedlickova Z, Burlakova I, Bug G, Baurmann H, Schwerdtfeger R, Schleuning M
Biol Blood Marrow Transplant
. 2010 Aug;
17(5):657-63.
PMID: 20696263
This retrospective study analyzes 34 patients with severe sclerodermatous chronic graft-versus-host disease (cGVHD) treated with inhibitors of the mammalian target of rapamycin (mTOR-I). Twelve patients received mTOR-I as monotherapy and...
10.
Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al.
Biol Blood Marrow Transplant
. 2010 Aug;
17(1):1-17.
PMID: 20685255
Steroid refractory chronic graft-versus-host disease (cGVHD) is associated with a significant morbidity and mortality. Although first-line treatment of cGVHD is based on controlled trials, second-line treatment is almost solely based...